Clinical trials: Small Bowel Bacterial Overgrowth
Systemic Sclerosis, Small Intestinal Bacterial Overgrowth
The Small Intestine Bacterial Overgrowth Study Pilot
This is a pragmatic study in which will compare a detailed treat-to-target (T2T) treatment algorithm to standard care for SSc SIBO at multiple sites around the world.
- Trial name
- SIBO (NCT03588845)
- Testing
- Treatment Protocol, Standard of Care
- Where
- 2 sites in United States, Australia
- Volunteers
- 500 people
- Sponsor
- Canadian Scleroderma Research Group
Irritable Bowel Syndrome, Small Intestinal Bacterial Overgrowth
Effect of a Probiotic Formula on Reducing SIBO in IBS Patients
This randomized study evaluates the effectiveness of the a probiotic formula, compared with the antibiotic rifaximin, in the treatment of Small Intestinal Bacterial Overgrowth (SIBO) in Irritable Bowel Syndrome (IBS) patients.
- Trial name
- NCT04316806
- Testing
- Probiotic, Rifaximin
- Where
- Spain
- Volunteers
- 8 people
- Sponsor
- AB Biotics, SA
Parkinson's Disease, Small Intestinal Bacterial Overgrowth
Treating Bacterial Overgrowth in Parkinson's Disease
This study investigates the effect of treating Small Intestinal Bacterial Overgrowth (SIBO) in patients with Parkinson's Disease (PD).
- Trial name
- SIBO-PD (NCT02470780)
- Testing
- Rifaximin
- Where
- United States
- Volunteers
- 4 people
- Sponsor
- University of Cincinnati
Cystic Fibrosis, Abdominal Pain
Rifaximin for Treatment of Bloating in Children and Adults With Cystic Fibrosis
Gastrointestinal symptoms are commonly reported in as much as 65% of people with CF even independent of pancreatic enzyme replacement therapy (PERT) and the most frequent of these symptoms are bloating/distension, flatulence…
- Conditions
- Cystic Fibrosis, Abdominal Pain, Small Bowel Disease
- Trial name
- NCT05408910
- Testing
- Rifaximin 550 MG Oral Tablet [XIFAXAN]
- Sponsor
- Wake Forest University Health Sciences
Small Intestinal Bacterial Overgrowth
Pilot Feasibility Study of Fecal Microbiota Transplant for the Treatment of Small Intestinal Bacterial Overgrowth
The objective of the study is to assess feasibility, and clinical efficacy of a novel Fecal Microbiota Transplantation protocol for the treatment of pediatric small intestinal bacterial overgrowth (SIBO).
- Trial name
- NCT05967871
- Testing
- Fecal Microbiota Transplant
- Where
- 2 sites in Canada
- Volunteers
- 20 people
- Sponsor
- McMaster Children's Hospital
Gastroesophageal Reflux, Small Intestinal Bacterial Overgrowth
Intestinal Adsorbent and Breath Gas Levels
To determine the effect of an intestinal adsorbent on hydrogen and methane breath levels in patients who have been on long term PPI therapy reporting reflux and abdominal symptoms at baseline.
- Trial name
- NCT04492839
- Testing
- Intestinal adsorbent
- Where
- United Kingdom
- Volunteers
- 20 people
- Sponsor
- Dr Anthony Hobson
Small Intestinal Bacterial Overgrowth, Small Intestinal Fungal Overgrowth
SIBO & SIFO After Colectomy
After subtotal colectomy, 40% of patients report abdominal pain, gas and diarrhea, and poor quality of life; whose etiology is unknown.
- Conditions
- Small Intestinal Bacterial Overgrowth, Small Intestinal Fungal Overgrowth, Colectomy
- Trial name
- NCT03216239
- Volunteers
- 100 people
- Sponsor
- Augusta University
Diarrhea Predominant Irritable Bowel Syndrome, Small Intestinal Bacterial Overgrowth
Use of SBI in IBS Subjects Following a Successful Treatment of Small Intestinal Bacterial Overgrowth
The primary objective of this study is to determine whether giving SBI as a medical food starting with maintenance of health in the management of chronic loose and frequent stools in IBS-D subjects with SIBO after successful…
- Trial name
- NCT02251483
- Testing
- Serum-derived bovine immunoglobulin protein isolate (SBI)
- Where
- United States
- Volunteers
- 2 people
- Sponsor
- Cedars-Sinai Medical Center
SIBO
Efficacy of Rifaximin in Patients With Small Intestinal Bacterial Overgrowth Presenting With Abdominal Bloating.
Abdominal bloating is a common clinical symptom in the digestive system, with obscure origins and complex mechanisms. Its etiology can be attributed to organic diseases and various Functional Gastrointestinal Disorders (FGIDs).
- Trial name
- NCT06772064
- Testing
- Rifaximin (drug)
- Where
- China
- Volunteers
- 115 people, healthy volunteers welcome
- Sponsor
- Xiuli Zuo
Small Intestinal Bacterial Overgrowth, Fecal Microbiota Transplantation
Clinical Study of Fecal Microbiota Transplantation in the Treatment of Small Intestinal Bacterial Overgrowth (SIBO)
Small intestinal bacterial overgrowth (SIBO) is defined as the presence of excessive numbers of bacteria in the small bowel causing gastrointestinal (GI) symptoms.
- Trial name
- NCT06162702
- Testing
- Fecal microbiota transplantation
- Where
- China
- Volunteers
- 66 people
- Sponsor
- Shanghai 10th People's Hospital
Small Intestinal Bacterial Overgrowth Syndrome (SIBO), Small Bowel Bacterial Overgrowth Syndrome (SBBOS)
Retrospective Analysis of Treatment Outcomes in Patients With Bacterial Overgrowth Syndrome Diagnosed by D-Xylose Breath Testing
The objective of this study is to compare the efficacy of prokinetics versus antibiotics versus a combination of antibiotics plus prokinetics in the eradication of Small-Intestinal Bacterial Over-Growth Syndrome (SIBO) in those…
- Trial name
- SIBO (NCT01324895)
- Where
- United States
- Volunteers
- 944 people
- Sponsor
- University of Florida
Irritable Bowel Syndrome, Small Intestinal Bacterial Overgrowth
The Efficacy of Probiotics as an Adjunct to Treatment of SIBO With Rifaximin
The goal of this clinical trial is to test the effectiveness of probiotic bacterial supplements as an additional therapeutic modality in patients with small intestine bacterial overgrowth who receive oral antibiotic treatment…
- Conditions
- Irritable Bowel Syndrome, Small Intestinal Bacterial Overgrowth, SIBO
- Trial name
- NCT06223685
- Testing
- Rifaximin (Xifaxan) 1200mg/day, Probiotic, XIFAXAN® (Rifaximin) 1600mg/day
- Where
- Poland
- Volunteers
- 129 people
- Sponsor
- Pomeranian Medical University Szczecin
Small Intestinal Bacterial Overgrowth
Feasibility of a New Diagnostic Device to Assess Small Intestinal Dysbiosis in Routine Clinical Setting.
The purpose of this study is to determine if the gas-sensing capsule can be used to identify increased numbers and a change of the composition of microbiota or microorganisms in the gut to assess small intestinal dysbiosis
- Trial name
- NCT04910815
- Testing
- Atmo Gas Capsule, Glucose Breath Test, Fructoolifosaccharides (FOS) Breath Test
- Where
- 2 sites in Australia, India
- Volunteers
- 110 people
- Sponsor
- Atmo Biosciences Pty Ltd
Irritable Bowel Syndrome, Abdominal Pain
Bifidobacterium Infantis M-63 Improves Mental Health in Irritable Bowel Syndrome Developed After a Major Flood Disaster
A 3-month study was conducted in flood victims from affected villages in the Tumpat district, Kelantan. Participants were given either probiotic, Bifidobacterium infantis M63 (M-63 group) or no probiotics (control group) for…
- Conditions
- Irritable Bowel Syndrome, Abdominal Pain, Small Intestinal Bacterial Overgrowth
- Trial name
- NCT03318614
- Testing
- Probiotics M-63, Control group
- Volunteers
- 53 people, healthy volunteers welcome
- Sponsor
- Universiti Sains Malaysia
Microbial Colonization, Small Intestinal Bacterial Overgrowth
High-fat Diet (HFD) and Small Intestinal Microbiome
The investigators aim to characterize the upper small intestinal microbiome in healthy conditions in dependency on feeding condition (starved vs.
- Trial name
- FATBOM (NCT07019142)
- Testing
- HFD
- Where
- Switzerland
- Volunteers
- 10 people, healthy volunteers welcome
- Sponsor
- Insel Gruppe AG, University Hospital Bern
Cirrhosis, Liver, Minimal Hepatic Encephalopathy
Rifaximin's Effect on Covert Hepatic Encephalopathy With SIBO and Gastrointestinal Dysmotility
Small Intestinal Bacterial Overgrowth (SIBO) is a common and increasingly recognized disorder in cirrhosis (30% to 73%). One of the most important predisposing factors of SIBO is small bowel dysmotility.
- Conditions
- Cirrhosis, Liver, Minimal Hepatic Encephalopathy, Small Intestinal Bacterial Overgrowth, Gastrointestinal Motility Disorder
- Trial name
- NCT04244877
- Testing
- Rifaximin
- Sponsor
- MetroHealth Medical Center
Irritable Bowel Syndrome
Efficacy of Rifaximin to Treat Diarrhea-predominant Irritable Bowel Syndrome
Irritable bowel syndrome (IBS) is a common disease and the pathogenesis of this disease includes central and peripheral mechanisms.
- Trial name
- NCT02565654
- Where
- China
- Volunteers
- 120 people, healthy volunteers welcome
- Sponsor
- First Affiliated Hospital, Sun Yat-Sen University
Bacterial Overgrowth Syndrome Small Bowel, Heart Failure with Preserved Ejection Fraction
Rifaximin and Cardiac Function in Patients with Heart Failure with Preserved Ejection Fraction
Single-center, double-blind, randomized, controlled intervention study of the effect of correction of bacterial overgrowth syndrome in the small intestine (SIBO) on cardiac function in patients with heart failure with preserved…
- Trial name
- SIBO-HFpEF (NCT06652087)
- Testing
- Rifaximin, Standard HFpEF treatment
- Where
- Russia
- Volunteers
- 40 people
- Sponsor
- I.M. Sechenov First Moscow State Medical University
Irritable Bowel Syndrome
Rifaximin for the Treatment of Irritable Bowel Syndrome
We have recently shown that the majority of patients with irritable bowel syndrome (IBS) have an abnormal lactulose breath test to suggest the presence of bacterial overgrowth of the small intestine.
- Trial name
- NCT00259155
- Testing
- Rifaximin
- Volunteers
- 92 people
- Sponsor
- Cedars-Sinai Medical Center
Irritable Bowel Syndrome
EFESO - EFficacy Enterogermina Small Intestinal Bacterial Overgrowth
Primary objective: to assess the efficacy of Bacillus clausii versus metronidazole in the eradication of the small intestinal bacterial overgrowth, 30 days after the end of treatment.
- Trial name
- NCT00331994
- Testing
- Bacillus clausii, Metronidazole
- Where
- Italy
- Volunteers
- 250 people
- Sponsor
- Sanofi